Alector Inc - Asset Resilience Ratio
Alector Inc (ALEC) has an Asset Resilience Ratio of 64.87% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Alector Inc's Asset Resilience Ratio has changed over time. Check Alector Inc strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Alector Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Alector Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $190.22 Million | 64.87% |
| Total Liquid Assets | $190.22 Million | 64.87% |
Asset Resilience Insights
- Very High Liquidity: Alector Inc maintains exceptional liquid asset reserves at 64.87% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Alector Inc Industry Peers by Asset Resilience Ratio
Compare Alector Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Alector Inc (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Alector Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 64.87% | $190.22 Million | $293.24 Million | -16.35pp |
| 2024-12-31 | 81.22% | $380.38 Million | $468.30 Million | +4.95pp |
| 2023-12-31 | 76.28% | $474.31 Million | $621.83 Million | +5.37pp |
| 2022-12-31 | 70.91% | $558.53 Million | $787.65 Million | +21.06pp |
| 2021-12-31 | 49.85% | $406.10 Million | $814.66 Million | -24.57pp |
| 2020-12-31 | 74.42% | $363.34 Million | $488.25 Million | +11.98pp |
| 2019-12-31 | 62.44% | $263.43 Million | $421.91 Million | -10.51pp |
| 2018-12-31 | 72.95% | $224.94 Million | $308.36 Million | -- |
About Alector Inc
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheim… Read more